PMLiVE |
Zafgen shares tumble after FDA places hold on diabetes trial
PMLiVE Shares in US specialist pharma company Zafgen plunged 41% yesterday to $5.41 after the FDA placed its lead candidate on clinical hold. The Boston-based company specialises in MetAP2 systems biology to develop novel therapies for patients affected by a ... FDA Halts Clinical Test of Zafgen Diabetes Drug, Stock Price Tumbles Officials with FDA Halt US Trials for Diabetes Drug Zafgen's IND for diabetes treatment placed on hold by FDA |
from diabetes - Google News
Social Plugin